GCC Dravet pricing runs on import-cost economics, not rebate negotiation. Cannabidiol's Schedule-1-equivalent classification adds USD 10-15K in compassionate-programme cost, while NPHC benchmarks new agents at no more than 3x stiripentol's SAR 30-50K reference price.
Pricing a Dravet-specific therapy in the GCC starts with a regulatory classification question, not a formulary negotiation. Cannabidiol (Epidiolex) is classified as a Schedule 1 equivalent narcotic under KSA and UAE federal law, the same category as heroin, so it moves only through Jazz Pharmaceuticals' compassionate-use programme at an annual cost of USD 10,000 to 15,000, plus SAR 5,000 to 8,000 in MOH/DHA import logistics per patient. Approval runs at an estimated 35 to 40% of applications at KFSH&RC and takes three to six months per case, the lowest approval rate of any rare-disease drug in the region. Stiripentol (Diacomit) carries no such barrier. It is not narcotics-classified, moves through standard hospital drug import via Biocodex's GCC distributor, and prices at SAR 30,000 to 50,000 a year.
NPHC has no formal Dravet coverage programme comparable to its SMA or PNH tracks; Dravet falls under the broader severe refractory paediatric epilepsy category and is evaluated case by case. That gap is starting to resolve into a WAC benchmark: NPHC's rare genetic epilepsy coverage framework signals it will price a new, non-narcotic Dravet agent at no more than three times the stiripentol reference price, roughly SAR 30,000 to 70,000 a year, unless the agent's efficacy data justifies a premium. Total annual per-patient cost today spans SAR 40,000 to 80,000 at the accessible, stiripentol-based tier, up to SAR 80,000 to 120,000 once cannabidiol's import cost is layered in. A pipeline agent's single largest commercial lever is clearing the SFDA Controlled Drug Board as non-narcotic; that step, not the WAC number itself, decides whether the agent prices like stiripentol or inherits cannabidiol's import-cost ceiling.
GCC Dravet pricing — import classification, not rebate, sets the ladder
| Agent | GCC Classification | Access Route | Annual Cost |
|---|---|---|---|
| Epidiolex (cannabidiol) | Schedule 1 equivalent narcotic | MOH/DHA exceptional import; 35-40% approval, 3-6 months | USD 10,000-15,000 + SAR 5,000-8,000 logistics |
| Diacomit (stiripentol) | Not narcotics-classified | Standard hospital import via Biocodex | SAR 30,000-50,000/yr |
| New non-narcotic entrant (modelled) | Contingent on SFDA Controlled Drug Board clearance | Standard import pathway, if cleared | Est. SAR 30,000-70,000/yr, capped at ~3x stiripentol |
Sources: Saudi MOH narcotics department drug import regulations; DHA exceptional import procedures UAE; NPHC rare genetic epilepsy coverage framework; KFSH&RC exceptional drug committee records 2023; Biocodex GCC pricing.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- MOH/DHA narcotics-import cost structure and approval-rate benchmarking
- the SFDA Controlled Drug Board classification pathway
- the pricing ceiling a narcotic classification imposes
Delivers
- NPHC's emerging 3x-stiripentol WAC benchmarking logic
- the rare genetic epilepsy coverage framework
- pricing scenarios bounded by the SAR 30-70K target
Delivers
- Stiripentol-based vs cannabidiol-inclusive cost tiers (SAR 40-120K)
- NPHC's case-by-case evaluation under the refractory paediatric epilepsy category
- access-tier-specific launch sequencing
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why SFDA narcotic classification, not a formulary negotiation, is the pricing gate any new GCC Dravet agent must clear first
- Pressure-tested against the cannabidiol import-cost precedent before the rest of the model is built out
- Cannabidiol, stiripentol, and a modelled new entrant positioned by classification status
- Where the import-cost gap sits between access tiers
- USD 10-15K annual cost plus SAR 5-8K import logistics decomposed
- The 35-40% approval rate and 3-6 month timeline
- SAR 30-50K standard hospital import pathway via Biocodex
- Why this is the pricing floor and benchmark anchor for new entrants
- The rare genetic epilepsy coverage framework's benchmarking logic
- Where efficacy data could justify a premium over the SAR 30-70K target
- SAR 40-120K total annual cost decomposed by access tier
- Stiripentol-based vs cannabidiol-inclusive scenarios
- Sequencing recommendation contingent on SFDA Controlled Drug Board clearance
- Conservative, base, and aggressive revenue scenarios by classification outcome
- The open pricing questions your team must close before the GCC launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory sources (SFDA, MOH, NPHC) and live registration-tracking documentation, not secondary summaries. Findings are independently verified before inclusion.
GCC Dravet syndrome pricing sources: Saudi MOH narcotics department drug import regulations, DHA exceptional import procedures (UAE), NPHC programme scope documentation and rare genetic epilepsy coverage framework, and KFSH&RC exceptional drug committee records 2023.
- Cannabidiol narcotics classification and approval rate verified against Saudi MOH narcotics department drug import regulations and KFSH&RC exceptional drug committee records 2023
- Stiripentol standard-import pricing verified against Biocodex GCC pricing data
- NPHC's Dravet scope gap and emerging WAC benchmarking verified against NPHC programme scope documentation and its rare genetic epilepsy coverage framework
Frequently asked questions
Commission this model
AXLRx delivers Dravet syndrome pricing strategy models built for market access and pricing teams navigating the GCC's narcotics-classification and import-cost dynamics. Custom model in 72 hours.
Specify your indication, target GCC country, and classification scenario.
AXLRx analyst confirms import-cost assumptions and NPHC benchmark before building.
Research-verified pricing model in 72 hours with optional analyst readout.